Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders



This is a prospective, phase II study evaluating the efficacy of a risk-adapted, personalized allo-HCT strategy based on geriatric vulnerabilities identified by pre-transplant GA. The less vulnerable/fit older patients are recommended to receive MA conditioning and the more vulnerable older patients are recommended to receive RIC/NMA conditioning.

  1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -> MA regimen
  2. HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> RIC/NMA regimen
    1. Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine
    2. Radiation therapy: total body irradiation (TBI)
    3. Other therapy: anti-thymocyte globulin (ATG)
SparkCures ID 1257
Trial Phase Phase 2
Enrollment 33 Patients
Trial Sponsors
  • Memorial Sloan Kettering Cancer Center
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Are 60 years or older
  • Have a pathologically confirmed myeloid malignancies including acute myeloid leukemia, ,myelodysplastic syndrome, myeloproliferative neoplasms, or related blood disorders including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative overlapping syndrome
  • Have <10% blasts in bone marrow prior to transplant
  • Have a matched related or unrelated donor, mismatched unrelated donor, or haploidentical donor
  • Meet institutional standard criteria for allogeneic transplantation as determined by the primary transplant physician
  • Undergoes transplantation using the allocated conditioning regimen intensity defined by the protocol-specified criteria below:
    • HCT-CI/Age <5 and IADL normal = myeloablative regimen
    • HCT-CI/Age ≥5 and/or IADL impairment = RIC/NMA regimen

Exclusion Criteria:

  • Prior hematopoietic cell transplantation
  • Cord blood donors
  • Persons with active, refractory disease defined by ≥10% blasts in bone marrow prior to transplant

US Trial Locations

Please visit the page for historical site information.

View Centers
SparkCures Verified

Learn more about how we work with trial sponsors